Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProQuad rHA 2-dose immunogenicity study in healthy children from 9 months of age
2007-002468-88Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2007
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of varicella virus vaccine in measles, mumps, rubella and 1 more (2 arms), sponsored by Sanofi. Primary endpoint: Antibody response rates to measles, mumps, rubella, and varicella at Day 42 after Dose 2. Started Jul 2007; status: completed.
02
Drugs
varicella virus vaccine
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2007-002468-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002468-88.